How Can we Treat Photophobia in Migraine

Status Completed

Clinical Trial Summary

Photophobia, the aberrantly increased sensitivity to light, is a common symptom in migraine patients and light discomfort is frequently found as a trigger for migraine attacks. In behavioral studies, planned exposure to light was found to reduce headache in migraineurs with photophobia, potentially by increasing habituation to this migraine trigger. Here, neurophysiological mechanisms of light exposure versus light deprivation therapy in migraine patients are investigated using functional magnetic resonance imaging (fMRI). Migraine patients and healthy controls receive light exposure therapy (Flash) and light deprivation therapy (Dark) for one hour daily on 7 consecutive days, in a crossover design with a wash-out period of three months. Study participants keep a diary including items on interictal and ictal photophobia, headache frequency and severity 7 days before, during, and 7 days after the interventions. One week before and one day after both interventions, fMRI using flickering light in a block design is applied. Functional activation is analyzed at whole-brain level and habituation of the visual cortex (V1) is modeled with the initial amplitude estimate and the corrected habituation slope.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05369910
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	N/A
Start date	April 1, 2015
Completion date	September 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01432379` - BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05048914` - Migraine Abortive Treatment
Completed	`NCT03662295` - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed	`NCT02766517` - Biomarker Study in Participants With Migraine	Early Phase 1
Completed	`NCT00963937` - Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents	Phase 3
Not yet recruiting	`NCT03632928` - Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
Completed	`NCT02559895` - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine	Phase 3
Completed	`NCT01435941` - Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine	N/A
Completed	`NCT00743015` - Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks	Phase 1
Completed	`NCT01376141` - Drug Use Investigation for IMIGRAN Tablet	N/A
Completed	`NCT02183688` - Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients	Phase 3
Completed	`NCT06061588` - "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"	N/A
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Completed	`NCT04091321` - Association Between Chronic Headache and Back Pain With Childbirth
Completed	`NCT00385008` - TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine	Phase 3
Active, not recruiting	`NCT05888298` - Proximal and Distal Approach GON RFT in Migraine	N/A
Completed	`NCT03435185` - Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients	N/A
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Completed	`NCT02565186` - An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine	Phase 3